New combo tackles tough lymphomas
NCT ID NCT05371054
First seen Dec 12, 2025 · Last updated May 19, 2026 · Updated 17 times
Summary
This study tested a three-drug combination (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had not responded to or returned after prior treatment. The main goals were to check safety and find the best dose. Participants took pills at home and received one drug through an IV at the clinic in 21-day cycles for up to 24 cycles, with follow-up for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.